AKT1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 3 clinical trials for lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 4 clinical trials for lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and lung carcinoma as inclusion criteria, 4 are phase 2 (3 open) [3].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MST1R is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NTRK2 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK2 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NTRK3 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].